The present invention relates generally to wearable, self-contained drug infusion devices that take advantage of the wearable nature of such devices to provide lower cost power components and communication components with lower power requirements and enhanced security as compared to wireless communication schemes.
Diabetes is a group of diseases marked by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. There are 23.6 million people in the United States, or 8% of the population, who have diabetes. The total prevalence of diabetes has increased 13.5% since the 2005-2007 time period. Diabetes can lead to serious complications and premature death, but there are well-known products available for people with diabetes to help control the disease and lower the risk of complications.
Treatment options for people with diabetes include specialized diets, oral medications and/or insulin therapy. The primary goal for diabetes treatment is to control the patient's blood glucose (sugar) level in order to increase the chances of a complication-free life. It is not always easy, however, to achieve good diabetes management, while balancing other life demands and circumstances.
Currently, there are two principal modes of daily insulin therapy. The first mode includes syringes and insulin pens that require a needle stick at each injection, typically three to four times per day, but are simple to use and relatively low in cost. Another widely adopted and effective method of treatment for managing diabetes is the use of a conventional insulin pump. Insulin pumps can help the user keep their blood glucose levels within target ranges based on their individual needs, by continuous infusion of insulin. By using an insulin pump, the user can match their insulin therapy to their lifestyle, rather than matching their lifestyle to how an insulin injection, for example, is working for them.
Conventional insulin pumps are capable of delivering rapid or short-acting insulin 24 hours a day through a catheter placed under the skin. Insulin doses are typically administered at a basal rate and in a bolus dose. Basal insulin is delivered continuously over 24 hours, and strives to keep one's blood glucose levels in a consistent range between meals and overnight. Some insulin pumps are capable of programming the basal rate of insulin to vary according to the different times of the day and night. Bolus doses are typically administered when the user takes a meal, and generally provide a single additional insulin injection to balance the carbohydrates consumed. Some conventional insulin pumps enable the user to program the volume of the bolus dose in accordance with the size or type of the meal consumed. Conventional insulin pumps also enable a user to take in a correctional or supplemental bolus of insulin to better control their blood glucose level to within their target range.
There are many advantages of conventional insulin pumps over other methods of diabetes treatment. Insulin pumps deliver insulin over time rather than in single injections and thus typically result in fewer large swings in one's blood glucose levels. Conventional insulin pumps reduce the number of needle sticks which the patient must endure, and make diabetes management easier and more effective for the user, thus considerably enhancing the quality of the user's life. Insulin pumps however can be cumbersome to use and are typically more expensive than other methods of treatment. From a lifestyle standpoint, the conventional pump, tubing, and injection set are inconvenient and bothersome for the user.
New advances in insulin therapy provide “wearable” drug infusion devices that are lower in cost and more convenient and comfortable to use than conventional insulin pumps. Some of these devices are intended to be partially or entirely disposable, and in theory provide many of the advantages of conventional insulin pumps without the initial high cost and inconvenience of conventional insulin pumps.
Wearable medical devices capable of performing similar functions as conventional insulin pumps are becoming increasingly more prevalent, but are still high in cost. Such medical devices are typically disposed of after a maximum of 3 days in operation. Driving factors for the duration of use for such medical devices include the viability of the injection site for a prolonged period and the limitations of the power supply in providing the necessary power over this period. Since common wearable medical devices are typically used for such short durations, it is necessary that the unit cost of each medical device be affordably low. In order to realize precise control over a user's insulin rate, typical wearable devices are required to communicate with a host device such as a Blood Glucose Monitor or a Personal Diabetes Monitor. Available wearable devices typically communicate with the host device using well-known wireless technology such as Bluetooth® or ZigBee®. Wireless communication technologies provide effective communication between the wearable device and a host device. However, the components necessary for realizing these technologies are relatively expensive, especially in an application using a disposable medical device. Not only do wireless communication technology components drive up the cost for providing the device, but they also consume sufficient power to shorten the life of the medical device, further driving up cost.
As indicated above, one major constraint of common wearable medical devices is the high cost of providing a reliable power supply for powering the necessary components to realize an effective and fully functional medical device. Further, there must be a balance in realizing a fully functional, affordable medical device and providing the medical device in a package that is convenient, comfortable and discreet for the user. Typical medical devices use a battery or battery array for providing power to the medical device. Such standard arrangements, however, unnecessarily drive up the cost of each medical device and can be bulky and relatively heavy. Further, the standard battery or battery array is usually disposed of at the same time as that of the used wearable medical device, thus contributing to unnecessary waste. Not until the cost of such medical devices is significantly reduced, will wearable medical devices be a viable option for many users.
Accordingly, there is a need in the art for providing more cost-effective wearable medical devices, so that many more diabetes patients can benefit from the advantages these devices provide.
Exemplary embodiments of the present invention address at least the above problems and/or disadvantages and provide at least the advantages described below. Accordingly, it is an object of exemplary embodiments of the present invention to provide lower power system components and an alternative energy source for powering the medical device that are lower in cost and capable of providing improved functionality and extended life of the wearable medical device. It is a further object of exemplary embodiments of the present invention to provide a device capable of communicating with a host controller and/or body sensor without the added component cost and power drain associated with wireless transceivers while also providing greater security over that of wireless transceivers.
According to one aspect of the present invention, a wearable medical device is provided in contact with a user's body for administering drug therapy to the user, the medical device comprising a microcontroller electrically coupled to a pump mechanism, a transceiver and a power supply system. The microcontroller commands the pump mechanism to administer a drug to the user. The transceiver communicates with a host device on or near the user's body via a personal area network (PAN) that transmits data across the user's body, wherein said host device monitors or controls the medical device. The power supply system selectively provides power to the microcontroller, pump mechanism and transceiver supplied from an energy harvesting component that harvests energy from the user's body. The personal area network transceiver communicates to the host device via an electric field generated on the user's skin at a contact site of the medical device on the user's body. The energy harvesting component stores energy realized by a thermal difference between the user's body and an external environment when the medical device contacts the user's body. The energy harvesting component may also store energy generated by the user's movement when the medical device is positioned on the user's body. The energy harvesting component provides at least a portion of the medical device's energy requirement. The medical device may further comprise an additional power source for providing at least a portion of power to the pump mechanism when actively administering a drug to the user in an active mode, wherein said energy harvesting component powers the medical device when in a lower power state such as a standby mode. The transceiver further communicates with a sensor implantable in the user's body, or in otherwise continuous contact with the user's body, via the personal area network. An embodiment also comprises a sensor electrically coupled to the microcontroller which is an ultra-low power microcontroller.
According to another aspect of the present invention, a medical device is provided in contact with a user's body for administering drug therapy to the user. The medical device comprises a housing in contact with a user's body. The housing further contains a microcontroller controlling a pump mechanism to deliver a drug at a contact site on the user's body. A power supply system comprising an energy harvesting component to harvest energy from the user's body is also provided. A harvested energy storage unit stores the harvested energy, and a power distribution unit selectively provides the stored energy to the microcontroller and the pump mechanism. The power distribution unit preferably provides a first power to the microcontroller when in an active mode, and supplies a second, lower power to the microcontroller in a standby mode of the medical device. The harvested energy storage unit provides at least a portion of the second power and the power supply system further comprises a battery to supply at least a portion of the first power. The housing may further contain a transceiver to communicate with a host monitoring device and a sensor in contact with the user's body via a personal area network that transmits data across the user's body.
A third aspect of the present invention provides a wearable medical device system for providing drug therapy to a user. The system comprises a wearable medical device provided in contact with the user's skin, said medical device comprising a pump mechanism for administering a prescribed volume of a liquid drug to the user. A bodily function sensor is provided in continuous contact with the user's body, and further in communication with the wearable medical device. The wearable medical device further comprises a microcontroller to control the prescribed volume of the drug according to physiological data received from the sensor, wherein the wearable patch pump and the sensor are at least partially powered by energy harvested from the user's body. The sensor may be contained in the wearable patch pump or when implanted in the user's body, the sensor communicates with the wearable patch pump via a personal area network that uses the user's body as a transmission medium to transmit the physiological data.
It is an object of another exemplary embodiment of the present invention to provide a method for administering drug therapy to a user through a wearable medical device in contact with a user's body. The method provides a microcontroller electrically coupled to a pump mechanism, a transceiver and a power supply system. The method configures the microcontroller to command the pump mechanism to administer a drug to the user and harvests energy from the user's body. The method configures the power supply system to selectively provide the harvested energy to the microcontroller, pump mechanism and transceiver and communicates with a host device on or near the user's body via a personal area network that transmits data across the user's body via the transceiver, wherein said host device monitors or controls the medical device and transmits data for at least controlling the administering of the drug to the user. Additionally, the method receives at the medical device said data transmitted via the personal area network from the host device and controls the pump mechanism to administer the drug to the user.
Objects, advantages and salient features of the invention will become apparent to those skilled in the art from the following detailed description, which, taken in conjunction with annexed drawings, discloses exemplary embodiments of the invention.
The above and other exemplary features and advantages of certain exemplary embodiments of the present invention will become more apparent from the following description of certain exemplary embodiments thereof when taken in conjunction with the accompanying drawings, in which:
Throughout the drawings, like reference numerals will be understood to refer to like elements, features and structures.
The matters exemplified in this description are provided to assist in a comprehensive understanding of exemplary embodiments of the invention, and are made with reference to the accompanying figures. Accordingly, those of ordinary skill in the art will recognize that various changes and modifications of the exemplary embodiments described herein can be made without departing from the scope and spirit of the claimed invention. Also, descriptions of well-known functions and constructions are omitted for clarity and conciseness.
A general embodiment of the wearable medical device 100, constructed in accordance with the present invention is illustrated in
As shown in
One of ordinary skill in the art will appreciate that medical device 100, shown in
A first exemplary embodiment of medical device 100 in accordance with the present invention is illustrated in
Microcontroller 104 in the first embodiment of the present invention is provided at least for controlling pump mechanism 102. Microcontroller 104 is preferably an ultra low-power (ULP) programmable controller, ideally operating in a range up to 3.6 V, which combines the necessary processing power and peripheral set to control drug delivery through the pump mechanism 102, monitor an optional sensor 300, and control any communication requirements for communicating with the host device 200. The first exemplary embodiment of the present invention provides a “smart” medical device that is capable of communicating with host device 200 via transceiver system 106. Microcontroller 104 is preferably fully programmable by the host device to precisely control the user's basal infusion rate and necessary bolus injections. Further, host device 200 can control microcontroller 104 to activate pump mechanism 102, perform system diagnostics, monitor system parameters of medical device 100 and record infusion data and other information communicated from medical device 100. Microcontroller 104 in the first embodiment is preferably embodied in a “system on a chip” (SoC) including the circuitry for the transceiver system 106. SoC designs usually consume less power and have a lower cost and higher reliability than the multi-chip systems that they replace. By providing a single chip system, assembly costs may be reduced as well.
Transceiver system 106, provided in medical device 100 in the first embodiment of the present invention, is compatible with the transceiver at the host device 200 and any other peripheral units such as optional bodily function sensor 300 in order to communicate with each device. As discussed above, in a “smart” medical device of the first embodiment, transceiver system 106 is provided for communicating at least system diagnostic data, infusion rate or infusion schedule information to host device 200 or some other external device. Additionally, transceiver system 106 receives commands and data from host device 200 enabling the programming of microcontroller 104 and control of other system functions of medical device 100. Diagnostic data can refer to any information about the functionality of the medical device and its system components, such as whether the cannula is blocked or otherwise rendered unusable, the remaining volume of liquid medicament available, and the remaining power available for controlling the medical device 100.
Conventional “smart” medical devices currently use radio frequency (RF) wireless communications such as Bluetooth®, Zigbee®, 802.11, or other conventional solutions. Some medical devices even communicate with the host device via a line-of-sight using infrared (IR) technology. Wireless communication systems, since they do not require a line of sight, are preferred over IR technology. Conventional wireless technology, however, is a driving contributor in the prohibitive cost of medical devices that use their respective technologies. Conventional wireless systems require an RF transceiver and antenna to operate. Advantageously, exemplary embodiments of the present invention use a capacitively coupled personal area network (PAN) to transceive data between medical device 100 and host device 200 through the user's skin, without the use of antennas. A personal area network, in the exemplary embodiments, can be created with simple, low-cost microcontrollers and analog components, requires less power to operate than RF systems and are at least as secure as RF systems. The use of a personal area network in the exemplary embodiments reduces the overall cost for device/host communications and enables extended use duration due to the reduced component cost and lower power requirements. As previously discussed, an exemplary PAN transceiver system 106 is preferably packaged in a SoC design with microcontroller 104 for further minimizing the overall cost of medical device 100.
PAN transceiver 106 preferably establishes a personal area network to communicate with host device 200 via a “near field” electric field that transmits data using the human body as a transport medium. Medical device 100 and host device 200 each need PAN transceivers 106 and 206, respectively, in order to communicate to each other through the body. In an exemplary personal area network as illustrated in
The above PAN communication system ensures that only people in direct contact with a user are capable of detecting the signals propagating across the user's body. Alternatively, in conventional wireless technologies, a transmitted signal can be detected by anyone with a receiver in the respective range of the wireless technology. Transmitters and receivers using Bluetooth® can transceive signals in a range from 30 ft. to 100 ft. Thus, PAN communication techniques are inherently more secure. However, additional techniques are desirable for coding and encrypting the transmitted current so that a user's private medical information cannot be detected or deciphered by anyone who comes into contact with the user. Coding techniques for preventing cross-talk between PAN devices is desirable so that a husband and wife, or other acquaintance, using PAN devices can hold or shake hands without influencing the data communication of either user's personal area network. Additionally, the signal transmitted across the user's body can be further encrypted so that any information transmitted by bodily contact will be unintelligible to unauthorized recipients. The specific techniques and methods for coding and encryption are not specific to the present invention. Any high reliability/low error version of a standard multi-user across single channel networking protocol, such as TCP/IP, can be effectively implemented in exemplary embodiments of the present invention. For instance, suitable handshaking techniques/protocols and encryption key management and algorithms for use in exemplary embodiments of the present invention may be similar to those currently used in Bluetooth® and Wi-Fi networks. It would be appreciated by one of ordinary skill in the art, that the particular coding and encryption techniques implemented in the exemplary embodiments of the present invention, while similar to those techniques discussed above, may be provided in a lighter, less complex protocol.
The necessary transceiver components for realizing the functionality of the exemplary personal area network discussed above, are widely available and relatively low in cost. Additionally, transceivers 106 and 206 can be realized in a single integrated circuit or included in the SoC design discussed above, which is even cheaper to produce and will consume even less power.
Analysis of a conventional medical device showed a typical steady state current usage of up to 15 mA while performing RF communications. Since an exemplary personal area network of the present invention transmits data using an ultra-low current signal propagating on the user's skin, data transfer can reasonably be achieved with 30 nA of current. Associated circuitry required to amplify and digitally acquire the data from the received electric signal could require up to 1 mA of additional current, thereby still achieving a factor of 10 reduction in power consumption for communications. Implementation of an exemplary PAN communication system in medical device 100 and host device 200, effectively realizes a significant decrease in power consumption for the device, thus resulting in less expensive, fewer or smaller power components for supplying the power necessary for system operations. A reduction in power requirements achieves an overall reduction in cost for the medical device 100 and reduces the number or size of power components, thus also reducing waste. Further, the low power requirements of the PAN communication system as well as the wearable nature of medical device 100 enable medical device 100 to utilize alternative energy sources for powering the device.
An exemplary embodiment of power system 108 utilizes a temporary storage circuit or device for storing the harvested charge until it is supplied to power a system component of medical device 100, such as PAN transceiver 106. An exemplary embodiment of the present invention utilizes an ultracapacitor as storage unit 114 to store the harvested energy. Ultracapacitors are advantageous because of their high energy density and quick charging times, thus providing a suitable option for powering the systems of an exemplary medical device 100. It should be appreciated by one of ordinary skill in the art, that storage unit 114 may comprise any temporary storage component, circuitry or technique that is known in the art, and is not particularly limited to an ultracapacitor. Power distribution unit 116, may comprise a power management circuit or other known component for providing the necessary power requirement from power storage unit 114 to each system device.
An exemplary embodiment of power system 108 in medical device 100 preferably comprises a single power source such as energy harvesting component 112, capturing, for instance, thermal or kinetic energy from the user's body and the user's natural movement. In an exemplary embodiment of the present invention comprising ultra low-power microcontroller 104 and low-power PAN transceiver system 106, a single energy harvesting source may be sufficient for providing the complete power requirements for medical device 100. Additionally, a single energy harvesting source may necessarily provide sufficient power for medical device 100 in embodiments that use a preprogrammed microcontroller 104 and do not provide a communications transceiver system. The power supplied to medical device should be sufficient for enabling operation of the medical device in an active mode and a standby mode. In the standby mode, the microcontroller preferably consumes about 10 microamperes of current but no more than 20 microamperes. In the active mode, the microcontroller preferably consumes about 10 milliamperes but no more than 20 milliamperes.
In some embodiments, power system 108 may additionally comprise a battery 118. Battery 118 may comprise any one of well known power storage units, or an array of such units, known in the art including, but not limited to, standard alkaline cells, rechargeable cells and ultracapacitors. In such embodiments, power distribution unit 116 can optimally manage the distribution of power from the battery 118 and the energy harvesting storage unit 114 to provide increased performance and extended life of medical device 100. One embodiment of medical device 100 would use battery 118 for long-term storage power or “off” mode, and in an active mode, such as during a high-discharge time for pump mechanism 102 to dispense a drug to the user. Harvested energy storage unit 114 is then preferably used to supplement the idle/standby mode of medical device 100, which has been shown in some systems to be the highest overall power drain to the system. By utilizing energy harvesting as the sole or partial power source for an exemplary embodiment of medical device 100, the device life could be extended or the battery requirements be reduced, thereby increasing performance and reducing cost in comparison to existing patch pumps.
Another embodiment of power system 108 for use in exemplary embodiments of the present invention is illustrated in
In the embodiment illustrated in
One of ordinary skill in the art would appreciate that the features of the above exemplary embodiments may be similarly provided in a number of applications and are not limited to the above disclosure. Any other skin-surface, wearable, implantable and handheld devices can all utilize the above features and techniques for providing a body based personal area network of complex, low-power devices at minimal cost. In addition to the insulin patch pump devices disclosed herein, other non-pump insulin infusion devices for patients of varying needs can be implemented with the above discussed features, such as a programmable insulin pen device or a controller in combination with an insulin absorption patch or electrosensitive gel patch. Additionally, other physiological information such as systolic pressure, heart rate and other metrics can all be monitored and captured via a respective device using the exemplary personal area network. Similarly, implantable defibrillators and other devices can all be controlled from a single master/host device. An exemplary personal area network can theoretically support many more than just two or three devices. Such network can also be used to communicate to any stationary devices when the user makes physical contact with them. One embodiment could provide automated data transmission such as populating patient records stored in a handheld or wearable device when touching a computer fitted with a compatible PAN transceiver. Another embodiment could provide emergency personnel with immediate data concerning a patient's physiological functions just by making skin to skin contact to establish a communications link between compatible devices on each person. As discussed above, each of these embodiments can be implemented in a secure PAN, so as to ensure user privacy and security of sensitive medical information.
While the present invention has been shown and described with reference to particular illustrative embodiments, it is not to be restricted by the exemplary embodiments but only by the appended claims and their equivalents. It is to be appreciated that those skilled in the art can change or modify the exemplary embodiments without departing from the scope and spirit of the present invention.
Number | Name | Date | Kind |
---|---|---|---|
3857382 | Williams, Jr. et al. | Dec 1974 | A |
3963380 | Thomas, Jr. et al. | Jun 1976 | A |
4204538 | Cannon | May 1980 | A |
4723947 | Konopka | Feb 1988 | A |
4755173 | Konopka et al. | Jul 1988 | A |
5176662 | Bartholomew et al. | Jan 1993 | A |
5226899 | Lee et al. | Jul 1993 | A |
5257980 | Van Antwerp et al. | Nov 1993 | A |
5453099 | Lee et al. | Sep 1995 | A |
5522803 | Teissen-Simony | Jun 1996 | A |
5536249 | Castellano et al. | Jul 1996 | A |
5545143 | Fischell | Aug 1996 | A |
5545152 | Funderburk et al. | Aug 1996 | A |
5593390 | Castellano et al. | Jan 1997 | A |
5728074 | Castellano et al. | Mar 1998 | A |
5820602 | Kovelman et al. | Oct 1998 | A |
5851197 | Marano et al. | Dec 1998 | A |
5858001 | Tsals et al. | Jan 1999 | A |
5858005 | Kriesel | Jan 1999 | A |
5925021 | Castellano et al. | Jul 1999 | A |
5957895 | Sage et al. | Sep 1999 | A |
5968011 | Larsen et al. | Oct 1999 | A |
5980506 | Mathiasen | Nov 1999 | A |
6017328 | Fischell et al. | Jan 2000 | A |
6056718 | Funderburk et al. | May 2000 | A |
6068615 | Brown et al. | May 2000 | A |
6074369 | Sage et al. | Jun 2000 | A |
6086575 | Mejslov | Jul 2000 | A |
6093172 | Funderburk et al. | Jul 2000 | A |
6104913 | McAllister | Aug 2000 | A |
6110148 | Brown et al. | Aug 2000 | A |
6115636 | Ryan | Sep 2000 | A |
6123690 | Mejslov | Sep 2000 | A |
6175752 | Say et al. | Jan 2001 | B1 |
6254586 | Mann et al. | Jul 2001 | B1 |
6272364 | Kurnik | Aug 2001 | B1 |
6275717 | Gross et al. | Aug 2001 | B1 |
6277627 | Hellinga | Aug 2001 | B1 |
6293925 | Safabash et al. | Sep 2001 | B1 |
6302866 | Marggi | Oct 2001 | B1 |
6352523 | Brown et al. | Mar 2002 | B1 |
6355021 | Nielsen et al. | Mar 2002 | B1 |
6391005 | Lum et al. | May 2002 | B1 |
6485461 | Mason et al. | Nov 2002 | B1 |
6520938 | Funderburk et al. | Feb 2003 | B1 |
6521446 | Hellinga | Feb 2003 | B2 |
6544212 | Galley et al. | Apr 2003 | B2 |
6546269 | Kurnik | Apr 2003 | B1 |
6551276 | Mann et al. | Apr 2003 | B1 |
6558351 | Steil et al. | May 2003 | B1 |
6565509 | Say et al. | May 2003 | B1 |
6576430 | Hsieh et al. | Jun 2003 | B1 |
6579267 | Lynch et al. | Jun 2003 | B2 |
6589229 | Connelly et al. | Jul 2003 | B1 |
6607509 | Bobroff et al. | Aug 2003 | B2 |
6656158 | Mahoney et al. | Dec 2003 | B2 |
6656159 | Flaherty | Dec 2003 | B2 |
6669669 | Flaherty et al. | Dec 2003 | B2 |
6692457 | Flaherty | Feb 2004 | B2 |
6699218 | Flaherty et al. | Mar 2004 | B2 |
6706159 | Moerman et al. | Mar 2004 | B2 |
6723072 | Flaherty et al. | Apr 2004 | B2 |
6740059 | Flaherty | May 2004 | B2 |
6749560 | Konstorum et al. | Jun 2004 | B1 |
6749587 | Flaherty | Jun 2004 | B2 |
6754472 | Williams et al. | Jun 2004 | B1 |
6768425 | Flaherty et al. | Jul 2004 | B2 |
6830558 | Flaherty et al. | Dec 2004 | B2 |
6830562 | Mogensen et al. | Dec 2004 | B2 |
6840922 | Nielsen et al. | Jan 2005 | B2 |
6852104 | Blomquist | Feb 2005 | B2 |
6949084 | Marggi et al. | Sep 2005 | B2 |
6960162 | Saadat et al. | Nov 2005 | B2 |
6960192 | Flaherty et al. | Nov 2005 | B1 |
6977180 | Hellinga et al. | Dec 2005 | B2 |
6997907 | Safabash et al. | Feb 2006 | B2 |
7004928 | Aceti et al. | Feb 2006 | B2 |
7018360 | Flaherty et al. | Mar 2006 | B2 |
7029455 | Flaherty | Apr 2006 | B2 |
7052251 | Nason et al. | May 2006 | B2 |
7064103 | Pitner et al. | Jun 2006 | B2 |
7070580 | Nielsen | Jul 2006 | B2 |
7083597 | Lynch et al. | Aug 2006 | B2 |
7109878 | Mann et al. | Sep 2006 | B2 |
7128727 | Flaherty et al. | Oct 2006 | B2 |
7137964 | Flaherty | Nov 2006 | B2 |
7144384 | Gorman et al. | Dec 2006 | B2 |
7207974 | Safabash et al. | Apr 2007 | B2 |
7214207 | Lynch et al. | May 2007 | B2 |
7226278 | Nason et al. | Jun 2007 | B2 |
7241266 | Zhou et al. | Jul 2007 | B2 |
7303543 | Maule et al. | Dec 2007 | B1 |
7303549 | Flaherty et al. | Dec 2007 | B2 |
7310544 | Brister et al. | Dec 2007 | B2 |
7318816 | Bobroff et al. | Jan 2008 | B2 |
7329239 | Safabash et al. | Feb 2008 | B2 |
7354420 | Steil et al. | Apr 2008 | B2 |
7496392 | Alarcon et al. | Feb 2009 | B2 |
7981085 | Ethelfeld | Jul 2011 | B2 |
7985199 | Kornerup et al. | Jul 2011 | B2 |
7985203 | Haueter et al. | Jul 2011 | B2 |
20020040208 | Flaherty et al. | Apr 2002 | A1 |
20030014091 | Rastegar et al. | Jan 2003 | A1 |
20030055380 | Flaherty | Mar 2003 | A1 |
20030109829 | Mogensen et al. | Jun 2003 | A1 |
20030176852 | Lynch et al. | Sep 2003 | A1 |
20030199823 | Bobroff et al. | Oct 2003 | A1 |
20040002682 | Kovelman et al. | Jan 2004 | A1 |
20040010207 | Flaherty et al. | Jan 2004 | A1 |
20040059316 | Smedegaard | Mar 2004 | A1 |
20040078028 | Flaherty et al. | Apr 2004 | A1 |
20040092865 | Flaherty et al. | May 2004 | A1 |
20040092878 | Flaherty | May 2004 | A1 |
20040116866 | Gorman et al. | Jun 2004 | A1 |
20040127844 | Flaherty | Jul 2004 | A1 |
20040153032 | Garribotto et al. | Aug 2004 | A1 |
20040204673 | Flaherty | Oct 2004 | A1 |
20040204687 | Mogensen et al. | Oct 2004 | A1 |
20040220551 | Flaherty et al. | Nov 2004 | A1 |
20040235446 | Flaherty et al. | Nov 2004 | A1 |
20040260233 | Garibotto et al. | Dec 2004 | A1 |
20050021005 | Flaherty et al. | Jan 2005 | A1 |
20050022274 | Campbell et al. | Jan 2005 | A1 |
20050043687 | Mogensen et al. | Feb 2005 | A1 |
20050065760 | Murtfeldt et al. | Mar 2005 | A1 |
20050090784 | Nielsen et al. | Apr 2005 | A1 |
20050101932 | Cote et al. | May 2005 | A1 |
20050101933 | Marrs et al. | May 2005 | A1 |
20050113761 | Faust et al. | May 2005 | A1 |
20050124936 | Mogensen et al. | Jun 2005 | A1 |
20050171512 | Flaherty | Aug 2005 | A1 |
20050182366 | Vogt et al. | Aug 2005 | A1 |
20050215982 | Malave et al. | Sep 2005 | A1 |
20050222645 | Malave et al. | Oct 2005 | A1 |
20050238507 | DiIanni et al. | Oct 2005 | A1 |
20050245799 | Brauker et al. | Nov 2005 | A1 |
20050273076 | Beasley et al. | Dec 2005 | A1 |
20050283144 | Shiono et al. | Dec 2005 | A1 |
20060041229 | Garibotto et al. | Feb 2006 | A1 |
20060074381 | Malave et al. | Apr 2006 | A1 |
20060129090 | Moberg et al. | Jun 2006 | A1 |
20060135913 | Ethelfeld | Jun 2006 | A1 |
20060142698 | Ethelfeld | Jun 2006 | A1 |
20060178633 | Garibotto et al. | Aug 2006 | A1 |
20060200073 | Radmer et al. | Sep 2006 | A1 |
20060263839 | Ward et al. | Nov 2006 | A1 |
20060264835 | Nielsen et al. | Nov 2006 | A1 |
20060281435 | Shearer et al. | Dec 2006 | A1 |
20060282290 | Flaherty et al. | Dec 2006 | A1 |
20060283465 | Nickel | Dec 2006 | A1 |
20070016149 | Hunn et al. | Jan 2007 | A1 |
20070021733 | Hansen et al. | Jan 2007 | A1 |
20070049865 | Radmer et al. | Mar 2007 | A1 |
20070073229 | Gorman et al. | Mar 2007 | A1 |
20070073559 | Stangel | Mar 2007 | A1 |
20070106199 | Krivoy et al. | May 2007 | A1 |
20070118405 | Campbell et al. | May 2007 | A1 |
20070191702 | Yodfat et al. | Aug 2007 | A1 |
20080004904 | Tran | Jan 2008 | A1 |
20080046038 | Hill et al. | Feb 2008 | A1 |
20080051697 | Mounce et al. | Feb 2008 | A1 |
20080051698 | Mounce et al. | Feb 2008 | A1 |
20080051709 | Mounce et al. | Feb 2008 | A1 |
20080051710 | Moberg et al. | Feb 2008 | A1 |
20080051711 | Mounce et al. | Feb 2008 | A1 |
20080051714 | Moberg et al. | Feb 2008 | A1 |
20080051716 | Stutz | Feb 2008 | A1 |
20080051718 | Kavazov et al. | Feb 2008 | A1 |
20080051727 | Moberg et al. | Feb 2008 | A1 |
20080051730 | Bikovsky | Feb 2008 | A1 |
20080051738 | Griffin | Feb 2008 | A1 |
20080051765 | Mounce | Feb 2008 | A1 |
20080058772 | Robertson et al. | Mar 2008 | A1 |
20080097321 | Mounce et al. | Apr 2008 | A1 |
20080097326 | Moberg et al. | Apr 2008 | A1 |
20080097327 | Bente et al. | Apr 2008 | A1 |
20080097328 | Moberg et al. | Apr 2008 | A1 |
20080097375 | Bikovsky | Apr 2008 | A1 |
20080097381 | Moberg et al. | Apr 2008 | A1 |
20080116647 | Anderson et al. | May 2008 | A1 |
20080119707 | Stafford | May 2008 | A1 |
20080132842 | Flaherty | Jun 2008 | A1 |
20080132881 | Wood et al. | Jun 2008 | A1 |
20080147041 | Kristensen | Jun 2008 | A1 |
20080160492 | Campbell et al. | Jul 2008 | A1 |
20080194924 | Valk et al. | Aug 2008 | A1 |
20080215006 | Thorkild | Sep 2008 | A1 |
20080261255 | Tolosa et al. | Oct 2008 | A1 |
20080264261 | Kavazov et al. | Oct 2008 | A1 |
20080269680 | Ibranyan et al. | Oct 2008 | A1 |
20080269713 | Kavazov | Oct 2008 | A1 |
20080294028 | Brown | Nov 2008 | A1 |
20080306434 | Dobbles et al. | Dec 2008 | A1 |
20080312608 | Christoffersen et al. | Dec 2008 | A1 |
20090005724 | Regittnig et al. | Jan 2009 | A1 |
20090005728 | Weinert et al. | Jan 2009 | A1 |
20090012472 | Ahm et al. | Jan 2009 | A1 |
20090076453 | Mejlhede et al. | Mar 2009 | A1 |
20090112178 | Behzadi | Apr 2009 | A1 |
20090118594 | Zdeblick | May 2009 | A1 |
20090163965 | Boyden | Jun 2009 | A1 |
20100222847 | Goetz | Sep 2010 | A1 |
Number | Date | Country |
---|---|---|
0980687 | Feb 2000 | EP |
1044374 | Oct 2008 | EP |
WO2007051139 | May 2007 | WO |
WO2008008281 (A2) | Jan 2008 | WO |
WO2008153769 (A1) | Dec 2008 | WO |
WO2009021039 | Feb 2009 | WO |
WO2009021052 | Feb 2009 | WO |
WO2009055204 (A1) | Apr 2009 | WO |
WO2009055733 (A1) | Apr 2009 | WO |
Entry |
---|
“Energy Harvesting, Micro Batteries and Power Management ICs: Competitive Environment,” Darnell Group, Jun. 11, 2007, <http://www.darnell.com/store/product—info.php?products—id=39>. |
“Micropower generation and storage,” IMEC, 2007, <http://www.imec.be/ScientificReport/SR2007/ html/1384267.html>. |
“Supercapacitors, KSL Series,” Cooper Bussmann, St. Louis, 2009, <http://www.cooperbussmann.com/ pdf/e81bf50c-96fb-42bb-ab61-733bb80e3a50.pdf>. |
Allan, Roger, “The Pulse Quickens for Cutting-Edge Medical Electronics Advances,” Electronic Design, Feb. 12, 2009, <http://electronicdesign.com/Articles/ArticleID/20625/20625.html>. |
Gupta, Puneet, “Personal Area Networks: Say It and You Are Connected,” Wireless Developer Network, 2009, <http://www.wirelessdevnet.com/channels/bluetooth/features/pans.html>. |
Hammerschmidt, Christoph, “Startup Launches RFID Alternative,” EE Times, Aug. 3, 2004, <http://www.eetimes.com/showArticle.jhtml?articleID=26805561>. |
Ident Technology AG, Wessling, Germany <www.skinplex.net>. |
Li, Q. et al., “Biomechanical energy harvesting: Apparatus and method,”, IEEE International Conferences on Robotics and Automation 2008, May 19-23, 2008, <http://ieeexplore.ieee.org/Xplore/login.jsp?url=/el5/4534525/4543169/04543774.pdf?arnumber=4543774>. |
Raju, Murugavel, “Energy Harvesting ULP meets energy harvesting: A game-changing combination for design engineers,” Texas Instruments, 2008, <http://www.ti.com/corp/docs/landing/cc430/graphics/ slyy018—20081031.pdf>. |
Seaman, Matthew, “Powering an MSP430 From a Single Battery Cell,” Application Report, SLAA398, Sep. 2008, Texas Instruments, <http://focus.ti.com/lit/an/slaa398/slaa398.pdf>. |
Thermo Life Energy Corp, “Thermolife Whitepaper,” 2008, <http://www.poweredbythermolife.com/whitepaper.htm>. |
Number | Date | Country | |
---|---|---|---|
20110022025 A1 | Jan 2011 | US |